Search Pharmacovigilance & Regulatory Intelligence

Users must ensure systems remain connected to power, conduct proper startup procedures, perform preoperative checks, and have emergency ventilation plans in place. Acknowledgment of receipt of the safety notice is required within 30 days.

Users are required to monitor inventory for affected lots and comply with instructions for potential disposal according to updated guidance from Microgenics Corporation.

Users must perform a software update to disable remote control and speed regulation for e-motion systems before January 1, 2021, using the Mobility application (version V01.004). For newer models, users need to safely store QR code labels after pairing.

Healthcare facilities are advised to adhere to standard acquisition protocols or modify parameters as recommended, with a requirement to respond to Philips within 30 days of notification.

Healthcare facilities using the affected Newport HT70 and HT70 Plus ventilators need to cease their use and evaluate the risk for their patients, following established protocols for device monitoring and replacement.

Healthcare facilities must initiate the removal process for affected lots, isolate impacted products, and communicate the recall information to all relevant healthcare professionals. Compliance with the outlined return process is mandatory.

Pharmacies within healthcare establishments must review the safety information and adhere to the guidance issued by ANSM regarding the usage of the device.

Surgifrance must implement corrective actions, including the establishment of processes for handling complaints in 3 months, and a complaints register within 8 months.

Pharmacovigilance systems must be updated to monitor and report on the newly added medications.

Ensure compliance with the updated reference list and adjust internal regulatory monitoring processes to align with the inclusion of new biologicals.

Increased vigilance and reporting obligations on illegal peptide products, with an emphasis on monitoring and managing safety signals pertaining to these substances.

AZRL LTD must proceed with the recall of FastPen 40mg from all locations and suspend marketing activities until compliance is verified.

Healthcare facilities must complete preoperative checks, manage emergency O2 flow during usage, and return the response form to GE Healthcare within a maximum of 30 days.

All users of the affected analyzers are required to reply to the notification letter within 10 days and implement increased monitoring of device performance to prevent liquid leaks.

Laboratories must immediately quarantine and return the affected product, and communicate with patients to manage their follow-up testing appropriately.

PV teams need to update Standard Operating Procedures (SOPs) for Signal Management to include enhanced monitoring guidelines for medication errors specifically related to RSV treatments. Additionally, teams should ensure proper communication of these updates to healthcare professionals involved in patient care.

Pharmacovigilance teams must update signal management processes to incorporate the new monitoring guidelines for injectable iron medicines. This includes reviewing current risk assessment processes and potentially updating medication guidelines to ensure compliance with the new recommendations.